New cell therapy takes on Drug-Resistant melanoma
Disease control
Not yet recruiting
This phase 2 trial tests a new cell therapy called RAPA-201 for people with advanced melanoma that has stopped responding to standard immunotherapy. The treatment uses a patient's own immune cells, specially trained to fight cancer. The study aims to see if this therapy can shrin…
Phase: PHASE2 • Sponsor: Rapa Therapeutics LLC • Aim: Disease control
Last updated May 20, 2026 12:08 UTC